Bruker Corporation (Nasdaq: BRKR) 2022 JP Morgan Healthcare Conference
IN N OVATION WITH IN TEG RIT YBruker Corporation (Nasdaq: BRKR)2022 JP Morgan Healthcare ConferenceFrank Laukien, Chairman, President & CEOJanuary 10, 2022
BRUKER CORPORATIONSafe Harbor StatementAny statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,including statements regarding our preliminary fourth quarter and fiscal year ended December 31, 2021 operational and financial performance,including our revenue growth, non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate; ROIC; EBITDA; management’s expectationsfor future financial and operational performance, expected growth, and business outlook; statements regarding our business focus, expectedmarket growth and market size; and product performance. Any forward-looking statements contained herein are based on current expectations,but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to,risks and uncertainties relating to the length and severity of the COVID-19 pandemic, the impact of the pandemic on global economic conditions,the impact of any supply chain disruptions, continued volatility in the capital markets, the impact of Project Accelerate, the performance ofbreakout opportunities, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, fluctuations inforeign currency exchange rates and their impact, our ability to successfully implement our restructuring initiatives and other cost reductioninitiatives, changing technologies, product development and market demand and acceptance of our products, the success of our R&Dinvestment initiatives, the cost and pricing of our products, manufacturing, competition, loss of key personnel, dependence on collaborativepartners, key suppliers and contract manufacturers, capital expenditures, debt levels, payment of dividends, government funding policies,changes in governmental regulations, the use and protection of intellectual property rights, litigation, and other risk factors discussed from timeto time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detailin our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2020, as may beupdated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements otherthan as required by law. 20212022 BrukerInnovation with Integrity January 10, 2022 2
BRUKER PRELIMINARY Q4 AND FY 2021 REVENUEPreliminary Q4-21 Revenue Range Above ExpectationsCapping off a Strong Growth Year 2021Preliminary Q4 and FY 2021 RevenueCurrent expectations: Q4 2021 revenue estimate of 665 - 670 million Reported Q4 YoY revenue growth 6.0% to 6.8%(1) Organic Q4 YoY revenue growth 8.4% to 9.2% FY 2021 revenue 2.4 billion Reported YoY revenue growth 20.8%(2) Organic YoY revenue growth 18.2%Because the Company’s financial statements for the fiscal year ended December31, 2021 have not yet been finalized or audited, the preliminary statementsregarding the Company’s expectations regarding its fourth quarter and fiscal year2021 revenue are subject to change, and the Company’s actual revenue growth forthis period may differ materially from this preliminary estimate. Accordingly, youshould not place undue reliance on this preliminary estimate.Reconciliation of non-GAAP financial measures to the most directly comparable GAAPmeasures is available at the end of this presentation. 20212022 Bruker(1) Q4-21 Reported YoY Revenue Growth includes FX impact of (-2.7%) and M&A impact of 0.3%(2) FY-21 Reported YoY Revenue Growth includes FX impact of 2.2% and M&A impact of 0.4%YTD Q3 2021 Financials (YoY) Revenue increased 374.4M, or 27.5% Organic growth of 22.6%, with BSI up 22.9% andBEST up 19.2%; Contribution from acquisitions of 0.5%, and FX tailwind of 4.4% Non-GAAP gross margin of 51.0%, up 370 bps Non-GAAP operating margin of 18.8%, up 590 bps Non-GAAP EPS of 1.51, up 96% compared to 0.77 inYTD Q3-20Non-GAAP EPSRevenues [ M]YTDQ3-201,734.41,360.0YTDQ3-21YTD Q3-21YTD Q3-20Innovation with Integrity January 10, 2022 3
BRUKER CORPORATIONRevenue Growth, Margin Expansion and EPSA solid track record of growth - with exceptional improvements in LTM 9/30/21(1)REVENUE ( B)2.0%(2.3%)3.6%4.3% Historical breakout opportunities in Proteomicsand Spatial BiologyMicrobiology and Molecular DiagnosticsBiopharma & AppliedSemi Metrology, Microelectronics ToolsAftermarket, Consumables & Software 20212022 Bruker3305.7%PROJECT ACCELERATE 2.0 NON-GAAP (2) EPSNON-GAAP (2) OPERATING MARGIN150909080OPERATIONAL EXCELLENCE Entrepreneurial Bruker Management ProcessR&D and product development excellenceEstablished shared services centersCommercial excellence, marketing innovationWorld-class manufacturing and outsourcing19%34%2%16%12%NON-OPERATIONAL DRIVERS Debt refinancing at favorable fixed interest ratesActive share repurchase programFX hedging programs(1) LTM 9/30/21 represents last twelve months financial performance ended 9-30-21. Please see reconciliation information available at the end of this presentation.(2) Reconciliations of non-GAAP operating margin and non-GAAP EPS to the most directly comparable GAAP measures are available at the end of this presentation.Innovation with Integrity January 10, 2022 4
Premier Provider of High-Performance Scientific Instruments,and Life Science Research & Diagnostic SolutionsDifferentiated. Innovative. Entrepreneurial. Long track record of technological innovation Culture of disciplined entrepreneurialism Extensive collaborations with renowned science labs Deep chemistry, biology & physics applications expertiseBreakout Opportunities inProteomics & Spatial Biology Global reach and scale Operational excellence and high ROICHigh Value. Operational Excellence. Sustainability. 2022 BrukerInnovation with Integrity January 10, 2022 5
DUAL STRATEGYOur Strategy Focuses on Accelerating Revenue Growth WhileContinuing to Deliver Sustainable Margin ExpansionProject Accelerate 2.0(1)Operational Excellence Innovation & growth Commercial excellence Significant margin expansion Product R&D excellence Expanded large TAMs At inflection point of expectedbreakout opportunities inproteomics and spatial biology Expanding margins High ROIC philosophy Sustainable success We build through innovation and disciplined entrepreneurialism, e.g., Microbiology, BioPharma, Phenomics, Semi Metrology We enable and pursue potential breakout opportunities in Proteomics and Spatial Biology We manage our core businesses for profitable growth, high ROIC and long-term, sustainable stakeholder success2021 Bruker 2022(1) Detailed description of Project Accelerate 2.0 initiatives available in the AppendixInnovation with Integrity January 10, 2022 6
DUAL STRATEGY – PROJECT ACCELERATE & OPERATIONAL EXCELLENCEOperational Excellence Driving innovation, growth,productivity and margins 2020-2021 CAPEX investments 100M p.a. for R&D, productivityand capacityExpanded Bruker Ettlingen facility, now with consolidatedBruker BioSpin German R&D and OperationsOperational EfficiencyCommercialExcellenceBruker Nano Penang Facility MalaysiaR&DExcellence PLC-driven R&D process BioSpin Productivity Project 2020-2021,site consolidation, capacity expansion Project Accelerate-focusedinvestments CALID investments 2021-2023 Biopharma tiger teams DfX for cost, service, outsourcing,platform leverage NANO lower cost & tax site Penang Extensive KOL collaborations Modernizing PDM and PLC BEST productivity and capacity ERP and CRM integration Continuous improvement via Lean Modernized marketing systems CE-IVD/FDA regulatorycompliance for DX 20212022 BrukerInnovation with Integrity January 10, 2022 7
PROJECT ACCELERATE 2.0 UPDATESMicrobiology & Molecular DX: Robust Microbiology Business GrowthMALDI Biotyper at accelerated DD revenue growth yoy in 2021 FY2021: 50% yoy U.S. order growth aided by Sepsityper FDA clearance in Dec. 2020 600 MBT units sold in 2021 globallySepsis: When every hour counts 5,000 UnitsSold GloballySepsis caused by arod-shapedbacterium2021 Bruker 2022MBT SepsityperIVD KitInnovation with Integrity January 10, 2022 8
PROJECT ACCELERATE 2.0 UPDATESNSF-Funded Network for Advanced NMR Orders Two 1.1 GHz NMRsNAN consortium to operate with ‘hub and spoke’ model to meet evolving scientific and disease biology needs University of Connecticut hub facilitating access to NMR instrumentation, experimental protocols and expertise 1.1 GHz NMR system ordered by University of Wisconsin - Madison for solid-state NMR research 1.1 GHz NMR system ordered by University of Georgia for solution-state NMR studies“The establishment of a geographicallydistributed Network for Advanced NMR (NAN) inthe U.S. is an innovative means to provide ultrahigh field NMR spectrometers for users to tackleimportant and diverse scientific problems and toeducate and train the next generation ofscientists and engineers.”Dr. Jeffrey Hoch, Professor ofMolecular Biology andBiophysics at UConn’s Schoolof Medicine 2022 Bruker“These 1.1 GHz-NMR systems will enablebreakthroughs for a diverse set of biologicalproblems, including structure, dynamics andfunction of systems ranging from organicmolecules and proteins to whole cells andtissues.”Dr. Katherine Henzler-Wildman,Professor of Biochemistry at theUniversity of Wisconsin atMadison“One of the best aspects of the NANconsortium will be the increased availability ofadvanced NMR technology to scientists acrossthe country. Remote users at any institutionwill be able to bring or send their samples toany NAN institution for data acquisition.”Dr. Arthur Edison, Professor ofGenetics and Biochemistry atthe University of GeorgiaInnovation with Integrity January 10, 2022 9
PROJECT ACCELERATE 2.0 UPDATESBioPharma: Multiple Solutions Leading to Rapid Growth Highly differentiated NMR, MS and FTIR/NIR solutions for drug discovery, binding assays, drug development,reaction monitoring, and process analytical technologies for small molecule drugs and biologics Market leading position in NMR and unique Mass Spectrometry biopharma solutionsNMR State-of-the-art GxP and QC AV NEO and Fourier 80 NMR Drug delivery: structural insights into lipid nanoparticlesDNP NMR Biologics similarity assessment,protein-excipient interaction,heparin, polysaccharide vaccinesAV NEO 600– 800 MHz NMR 2022 BrukerMass Spectrometry timsTOF biopharma revenue 30% YoY Label-free ultra-HTP screening withMALDI PharmaPulse solution Spatial drug and metabolite distributionby timsTOF fleX and MRMS MS Imaging Biologics: superior characterization ofproteins, HCP, oligos, mAbs, ADCs:intact mass, PTMs, disulfide bonds,glycosylationInnovation with Integrity January 10, 2022 10
PROJECT ACCELERATE 2.0 UPDATESBenchtop FourierTM 80 FT-NMR Fourier 80 benchtop system enables FT-NMR without cost, space,cryogens or expertise for superconducting high-field NMR Product innovations in 2021: Gradient spectroscopy standard for throughput and better results Industry-leading automation options Launches Europe (2020), Americas (H1-21) and APAC (H2-21) Rapid adoption already with 50 units sold in FY2021 Global ramp-up in 2022 Additional capabilities to launch throughout 2022Gradient-spectroscopy Fourier 80 with PAL sample changer Applied and Industrial solutions under developmentBruker democratizing NMR with next-generation, robustand high-performance, automated benchtop FT-NMR2021 Bruker 2022Innovation with Integrity January 10, 2022 11
BREAKOUT OPPORTUNITY - 4D PROTEOMICStimsTOF 4D-Proteomics timsTOF Installed Base timsTOF platform installed base 425 425 units at end of 2021 300Large-cohort plasmaproteomics, PTMsTissue & cell cultureproteomics, PTMs timsTOF revenue growth 30% yoyto 100M in FY202120202021SCPUltra-high sensitivityfor 4D-Multiomics2021 Bruker 2022MALDI SpatialOMx &ESI MultiomicsExtreme sensitivity for SingleCell Proteomics (SCP)Biopharma proteomics,PTMs, mAbs, ADC, HCPsCancer FNA multiomics &LBx multiomics discovery,cancer glycomicsBreakthrough: unbiased,deep and quantitative SCPInnovation with Integrity January 10, 2022 12
BREAKOUT OPPORTUNITY - 4D PROTEOMICSUltra-high sensitivity timsTOF SCP forunbiased, deep single-cell proteomics Perfectly complements scRNA-seq 3,500 proteins, 25k peptides at 5ng loaded Mann et al. SCP publication: 1,500 protein groups quantified insingle cells after laser capture microdissection for cell selection Multiclonal cancer cells, stroma and immune cellheterogeneity of tumor microenvironment (TME)SCP High-sensitivity neoantigen discovery in immuno-oncology“I always said that single cell proteomics would not happenin my lifetime, but I’m happy to have been proven wrong.”2021 Bruker 2022Prof. Matthias MannInnovation with Integrity January 10, 2022 13
BREAKOUT OPPORTUNITY - SPATIAL BIOLOGYLeveraging Our Fluorescence Imaging Technology forSpatial Biology and Cellular ial AnalysisMethodso Canopy Biosciences ChipCytometryfor high plex targeted spatial proteomicsPROTEOMICSo Vutara: versatile super-resolutionbiological imaging platformTRANSCRIPTOMICSo Acuity Spatial Genomics opening upnew frontiers in 3D genome in situGENOMICSGRANULARITY OFINFORMATION2021 Bruker 20223 platforms for spatial in situBulk averageinformationSingle cell, ex situinformationIn situ spatial,single-cellresolutionIn situ spatial,sub-cellularresolutionIncreased InsightInnovation with Integrity January 10, 2022 14
BREAKOUT OPPORTUNITY - SPATIAL BIOLOGYCanopy Launches Targeted Proteomics Kits for ChipCytometryTM Canopy assay kits are validated and optimized for Canopy ZellScannerONEinstrument to quantitatively image dozens of targeted protein biomarkerssimultaneously on a single tissue section at single-cell spatial resolution Single-cell targeted proteomics on 10,000s of cells in situ Unique: 8 orders of magnitude dynamic range The Spatial Immune Profiling Kit was launched in December 2021 formultiplexed, quantitative spatial phenotyping of key immune cellpopulations in human formalin-fixed paraffin-embedded (FFPE) tissuesFluorescent image of human lung cancer FFPE sample with 13protein biomarkers illuminated using the Spatial ImmuneProfiling Kit for Chip CytometryCanopy ChipCytometry kits provide researchers with reliable, ready-touse solutions - extensively validated in a variety of tissue types2021 Bruker 2022Innovation with Integrity January 10, 2022 15
NUCLEAR MOLECULAR IMAGING (NMI) ACQUISITIONAcquisition of MOLECUBES Strengthens NMI for Preclinical ImagingMOLECUBES is a dynamic innovator in benchtop preclinical NMI systemsModular benchtop CUBES NMI systems of MOLECUBES PET, SPECT, and CT CUBES , with global installed base of 70 systems Pre-acquisition Euro 5M in revenueMOLECUBES joins Bruker BioSpin Preclinical Imaging Division Modular benchtop CUBES complement Bruker’s integrated, floor-standingpreclinical imaging systems Broadens NMI portfolio for academic medical centers and biopharma Accelerates drug development and translational researchI-124 PET imaging in nanomedicine 20212022 BrukerInnovation with Integrity January 10, 2022 16
BRUKER CORPORATIONRecent Investments and Financial DevelopmentsInvestin Growing the BusinessMaintainFinancial FlexibilityReturnCapital to Shareholders R&D investments of 9-10% of revenue p.a. 500M Private Placement in Dec. Planned annual dividend increase to CAPEX investments 100M p.a. in 2020and 2021 for productivity and capacity Strategically-focused M&A and minorityinvestments 65M in FY20212021 to support strategic initiatives 10-year notes at 1% fixed rates Strong financial condition 0.20 per share, starting in FY2022(1) Up to 500M 2-year share repurchaseauthorized by Board in May 2021 BRKR added to S&P MidCap 400 Index inDec. 2021 60M in FY2020 2021 Bruker(1) Subject to quarterly Board approvalInnovation with Integrity January 10, 2022 17
BRUKER CORPORATIONBruker Building Momentum - Setting Up for a Solid 2022timsTOF 4D-ProteomicsSpatial Biology &Single-Cell OmicsMALDI Biotyper &LiquidArray PanelsMicrobiology & MDxUnique Portfolio of Life-Science andClinical Research SolutionsAddressing Breakout Opportunities Proteomics Spatial Biology 2022 BrukerNMR FunctionalStructural BiologyUnique BiopharmaSolutions for BiologicsSemi Metrology &MicroelectronicsHealthy End Markets and Operational ExcellenceDriving Core and Project Accelerate 2.0 BioPharma Growth with unique NMR and MS solutions Strong ACA/GOV, Applied and Industrial markets Flagship Product Adoption Strong growth in Semiconductor Metrology MALDI Biotyper DD growth, potential in US market timsTOF 4D-Proteomics technology transformationalInnovation with Integrity January 10, 2022 18
Appendix19
PROJECT ACCELERATE 2.0Faster Growth from Six Expanded High-Growth, High-Margin InitiativesConsumables, ScientificSoftware & AftermarketConsumables, assays, services,libraries & scientific softwareNext-gen NanomaterialsResearch & Semi MetrologyEnabling R&D and QC of nextgen logic, memory, displays,renewable energy, nanotoolsand nanomaterialsSpatial Biology, Single-CellOmics, and Cellular AnalysisSuper-resolution microscopy &cytometry for immunology,oncology, single-cell andsubcellular spatial biology andtargeted multiomics;Acuity Spatial 3D Genomics 20212022 BrukerUnbiased 4D-Proteomics &Epiproteomics, FunctionalStructural Biology, SCPUnbiasedProteomics &MultiomicsBiopharma &AppliedAssays, Software& AftermarketProteomics, PTMs, multiomicLBx, tissue SpatialOMx,functional structural biology,biomolecular condensates,unbiased single-cell proteomicsBiopharma & AppliedNext-gen Nano& Semi ToolsMicrobiology &Molecular DxHigh-value NMR, MS andFTIR/NIR solutions for drugdiscovery, development andpharma PAT; Applied foodanalysis and forensicsMicrobiology & Molecular DxSpatial Biology,Single-Cell Omics,Cellular AnalysisHigh-value solutions for faster,accurate and broadly scalableinfectious disease diagnostics,including viral MDxInnovation with Integrity January 10, 2022 20
BRUKER CORPORATIONReconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(in millions, except per share amounts)Twelve Months Ended December 31,2016 (1)Revenue2017 (1)20182019Three MonthsEndedDecember 31,Nine MonthsEndedSeptember 30,Last TwelveMonths EndedSeptember 30,2020202120212020 1,611.3 1,765.9 1,895.6 2,072.6 1,987.5 627.5 1,734.4 2,361.9GAAP Operating IncomeNon-GAAP Adjustments:Restructuring CostsAcquisition-Related CostsPurchased Intangible AmortizationOther CostsTotal Non-GAAP Adjustments: 181.8 219.5 262.4 300.9 248.3 112.8 287.9 400.7 20.811.121.77.160.7 16.210.229.65.461.4 9.47.328.99.955.5 1.416.838.36.663.1 15.83.235.714.268.9 10.13.78.95.628.3 5.23.927.22.238.5 15.37.636.17.866.8Non-GAAP Operating IncomeNon-GAAP Operating Margin Reconciliation of Non-GAAP Operating Income, Non-GAAP ProfitBefore Tax, Non-GAAP Net Income, and Non-GAAP EPSNon-GAAP Interest & Other Expense, netNon-GAAP Profit Before Tax242.515.0% 280.915.9% 317.916.8% 364.017.6% 317.216.0% 141.122.5% 326.418.8% )(0.8)(3.6)(2.4)(3.2)(5.6)Non-GAAP Net Income Attributable to ted Average Shares Outstanding AP Income Tax ProvisionNon-GAAP Tax RateMinority InterestNon-GAAP Earnings Per Share(1)The 1.19 1.21 1.40 1.57 1.35 0.58 1.51 2.09Company adopted Accounting Standards Update (ASU) 2017-07 as of January 1, 2018 under the retrospective approach. Accordingly, the 2016 and 2017 income statement accounts have been restated to reflect ASU 2017-07.2021 Bruker 2022Innovation with Integrity January 10, 2022 21
BRUKER CORPORATIONReconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(in millions, except per share amounts)Twelve Months Ended December 31,2016Reconciliation of GAAP and Non-GAAP Gross ProfitGAAP Gross ProfitNon-GAAP Adjustments:Restructuring CostsAcquisition-Related CostsPurchased Intangible AmortizationOther CostsTotal Non-GAAP Adjustments:Non-GAAP Gross ProfitNon-GAAP Gross Margin (1)745.311.02.118.70.131.9777.248.2%2017 (1) Reconciliation of GAAP and Non-GAAP Selling, General and Administrative (SG&A) ExpensesGAAP SG&A Expenses 389.8 Non-GAAP Adjustments:Purchased Intangible Amortization3.0Non-GAAP SG&A Expenses 386.8 (1)The816.05.65.724.00.836.1852.148.3%2018 2019900.02.63.921.60.628.7928.749.0% Three MonthsEndedDecember 31,Nine MonthsEndedSeptember 30,Last TwelveMonths EndedSeptember 0.0% 939.83.80.819.93.728.2968.048.7% 313.02.50.34.83.811.4324.451.7% 868.01.60.115.00.116.8884.851.0% 1,181.04.10.419.83.928.21,209.251.2% 415.2 444.7 500.2 468.6 130.4 407.9 538.35.6409.6 7.3437.4 14.9485.3 15.8452.8 4.2126.2 12.2395.7 16.4521.9Company adopted Accounting Standards Update (ASU) 2017-07 as of January 1, 2018 under the retrospective approach. Accordingly, the 2016 and 2017 income statement accounts have been restated to reflect ASU 2017-07.2021 Bruker 2022Innovation with Integrity January 10, 2022 22
BRUKER CORPORATIONReconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(in millions, except per share amounts)Twelve Months Ended December 31,2016 (1)Reconciliation of GAAP and Non-GAAP Tax RateGAAP Tax RateNon-GAAP Adjustments:Tax Impact of Non-GAAP AdjustmentsValuation Allowance ReleaseU.S. Tax Reform- Toll ChargeU.S. Tax Reform- Tax Rate ChangeU.S. Tax Reform- Change in APB 23Other Discrete ItemsTotal Non-GAAP Adjustments:Non-GAAP Tax RateReconciliation of GAAP and Non-GAAP Earnings Per Share (Diluted)GAAP Earnings Per Share (Diluted)Non-GAAP Adjustments:Restructuring CostsAcquisition-Related CostsPurchased Intangible AmortizationOther CostsBargain Purchase GainIncome Tax Rate DifferentialTotal Non-GAAP Adjustments:Non-GAAP Earnings Per Share (Diluted)(1)The2017 (1)20182019Three MonthsEndedDecember 31,Nine MonthsEndedSeptember 30,Last TwelveMonths EndedSeptember .2%25.2% 0.95 0.130.070.140.04(0.06)(0.08)0.241.19 0.49 0.100.060.190.040.330.721.21 1.14 0.060.050.180.06(0.09)0.261.40 1.26 0.010.110.240.04(0.09)0.311.57 1.02 0.100.020.230.09(0.11)0.331.35 0.45 0.070.020.060.04(0.06)0.130.58 1.32 0.030.030.180.01(0.06)0.191.51 1.77 0.100.050.240.05(0.12)0.322.09Company adopted Accounting Standards Update (ASU) 2017-07 as of January 1, 2018 under the retrospective approach. Accordingly, the 2016 and 2017 income statement accounts have been restated to reflect ASU 2017-07.2021 Bruker 2022Innovation with Integrity January 10, 2022 23
BRUKER CORPORATIONReconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(in millions, except per share amounts)Twelve Months Ended December 31,2016Reconciliation of GAAP and Non-GAAP Interest & Other Income (Expense), netGAAP Interest & Other Income (Expense), net Non-GAAP Adjustments:Bargain Purchase GainNon-GAAP Interest & Other Income (Expense), net Reconciliation of Impact of Adoption of ASU 2017-07 (2)Cost of revenuesSelling, general and administrativeResearch and developmentInterest and other income (expense), netNet Impact to Net Income and Earnings per Share:(1)The(1)2017 (1)20182019Three MonthsEndedDecember 31,Nine MonthsEndedSeptember 30,Last TwelveMonths EndedSeptember 30,2020202120212020(4.2) (21.7) (17.7) (20.5) (22.5) (7.1) (13.8) (20.9)(9.2)(13.4) (0.6)(22.3) (17.7) (20.5) (22.5) (7.1) (13.8) 1.1)(0.7)3.9-Company adopted Accounting Standards Update (ASU) 2017-07 as of January 1, 2018 under the retrospective approach. Accordingly, the 2016 and 2017 income statement accounts have been restated to reflect ASU 2017-07.2021 Bruker 2022Innovation with Integrity January 10, 2022 24
BRUKER CORPORATIONYTD Q3 2021 Reconciliation of GAAP Revenue Growth to Organic RevenueGrowth (Unaudited)Nine Months EndedSeptember 30,2021Total Bruker1,360.0(in millions)Reconciliation of GAAP Reported Revenue Growth to Organic Revenue GrowthGAAP Revenue as of Prior Comparable PeriodNon-GAAP Adjustments:Acquisitions and divestituresOrganicCurrencyTotal Non-GAAP Adjustments:Non-GAAP RevenueRevenue GrowthOrganic Revenue GrowthReconciliation of GAAP Reported Revenue Growth to Organic Revenue GrowthGAAP Revenue as of Prior Comparable PeriodNon-GAAP Adjustments:Acquisitions and divestituresOrganicCurrencyTotal Non-GAAP Adjustments:Non-GAAP RevenueRevenue GrowthOrganic Revenue GrowthReconciliation of GAAP Reported Revenue Growth to Organic Revenue GrowthGAAP Revenue as of Prior Comparable PeriodNon-GAAP Adjustments:Acquisitions and divestituresOrganicCurrencyTotal Non-GAAP Adjustments:Non-GAAP RevenueRevenue GrowthOrganic Revenue Growth(1) 6.3307.460.7374.41,734.427.5%22.6% Bruker Scientific Instruments (1) 1,235.36.3283.453.9343.61,578.927.8%22.9% BEST, net of IntercompanyEliminations 124.724.06.830.8155.524.7%19.2%Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI Life Science and BSI Nano Segments as presented in our 2020 Form 10-K.2021 Bruker 2022Innovation with Integrity January 10, 2022 25
Rapid adoption already with 50 units sold in FY2021 Global ramp-up in 2022 Additional capabilities to launch throughout 2022 Applied and Industrial solutions under development Bruker democratizing NMR with next-generation, robust and high-performance, automated benchtop FT-NMR Gradient-spectroscopy Fourier 80 with PAL sample changer
NETRCHFMH NASDAQ -100 Equal Weighted Currency Hedged CHF TR Index CHF NETRNNRCHFMH NASDAQ -100 Equal Weighted Currency Hedged CHF NTR Index CHF NDXG02MH Nasdaq-100 ESG Currency Hedged CAD Index CAD NDXG12MH Nasdaq-100 ESG Total Return Currency Hedged CAD Index CAD NDXG22MH Nasdaq-100 ESG Notional Net Total Return Currency Hedged CAD Index CAD .
To be eligible for continued inclusion in the NASDAQ-100 Index ("The Index"), an Index Security4 must meet the following criteria: the issuer of the security's primary U.S. listing must be exclusively listed on the NASDAQ Global Select Market or the NASDAQ Global Market the security must be issued by a non-financial company5;
Feb 19, 2022 · Miami-Dade County Daily Covid-19 Hospital Report Category 02/05/2022 02/06/2022 02/07/2022 02/08/2022 02/09/2022 02/10/2022 02/11/2022 02/12/2022 02/13/2022 02/14/2022 02/15/2022 02/16/2022 02/17/2022 02/18/2022 Beds Acute Care Beds Beds that may be converted to Acute Care Beds IC
Keymaster Technologies acquires C-Thru 2001 2001 Tracer 1 Keymaster introduces the first tube-based portable XRF 2005 TRACER III-V 2006 OEM Product 2006 Bruker acquires Keymaster Technologies 2009 S1 SORTER 2008 S1 TURBO SD 2008 Bruker introduces first SDD-based XRF 2012 S1 TITAN 20
which will be delivered to the DFSA and NASDAQ Dubai. Any Global Certificate will be deposited on or about each Issue Date with, and registered in the name of, NASDAQ Dubai Guardian Limited, which will act as bare nominee on behalf of NASDAQ Dubai Central Securities Depository (NASDAQ Dubai CSD). Interests in each Global Certificate may be held
TSLA GOOGL Technology 47.95% 908 318 19 10.02% 18.98% PAYPAL HOLDINGS INTEL CORP The Nasdaq Composite Index measures all Nasdaq domestic and international based common type stocks listed on The Nasdaq Stock Market. To be eligible for inclusion in the Index, the security's U.S. listing must b
Mar 11, 2020 · NASDAQ FIX Programming Specification 3/11/2020 7 2.3.1.1 Logon/Logoff FIX Startup FIX Shutdown 4:00 a.m. ET 8:00 p.m. ET NASDAQ FIX will be up and accessible at 4:00 a.m. NASDAQ FIX will remain up and running until 8:00 p.m. Although it is not required, we suggest you log off at the end of your trading day.
Abrasive Water Jet Machining (AWJM) is the non-traditional material removal process. It is an effective machining process for processing a variety of Hard and Brittle Material. And has various unique advantages over the other non-traditional cutting process like high machining versatility, minimum stresses on the work piece, high flexibility no thermal distortion, and small cutting forces .
